

Kentucky Department for Medicaid Services

Drug Review Options

The following chart lists the agenda items scheduled and the options submitted for review at the December 16, 2004, meeting of the Pharmacy and Therapeutics Advisory Committee.

ITEM	Options For Consideration
Influenza Antiviral Agent Review	<ol style="list-style-type: none">1. The influenza antiviral agents are considered to be equivalent for safety and efficacy.2. Select one agent in the adamantane class for the PDL based on lowest effective net cost.3. Select one neuraminidase inhibitor for the PDL based on lowest effective net cost.4. For any new chemical entity in the antiviral influenza agent class require a PA and quantity limit until reviewed by the P&T Advisory Committee.